Citadel Advisors’s Insmed INSM Stock Holding History

Citadel Advisors’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.31M	Sell	50,800 -168,000	-77%	-$25.8M	﹤0.01%	3519
2025 Q4	$38.1M	Buy	218,800 +23,900	+12%	+$4.36M	0.01%	1665
2025 Q3	$28.1M	Buy	194,900 +86,000	+79%	+$10.5M	﹤0.01%	1938
2025 Q2	$11M	Buy	108,900 +41,400	+61%	+$3.17M	﹤0.01%	2904
2025 Q1	$5.15M	Sell	67,500 -83,000	-55%	-$6.35M	﹤0.01%	3822
2024 Q4	$10.4M	Sell	150,500 -128,800	-46%	-$9.28M	﹤0.01%	2938
2024 Q3	$20.4M	Sell	279,300 -36,500	-12%	-$2.69M	﹤0.01%	2030
2024 Q2	$21.2M	Buy	315,800 +187,500	+146%	+$7.27M	﹤0.01%	1942
2024 Q1	$3.48M	Buy	128,300 +115,800	+926%	+$3.24M	﹤0.01%	4551
2023 Q4	$387K	Sell	12,500 -77,600	-86%	-$2.01M	﹤0.01%	8637
2023 Q3	$2.28M	Buy	90,100 +68,600	+319%	+$1.57M	﹤0.01%	4989
2023 Q2	$454K	Buy	21,500 +11,200	+109%	+$213K	﹤0.01%	8158
2023 Q1	$176K	Sell	10,300 -5,600	-35%	-$109K	﹤0.01%	10391
2022 Q4	$318K	Buy	15,900 +2,000	+14%	+$38.7K	﹤0.01%	9195
2022 Q3	$299K	Buy	+13,900	New	+$333K	﹤0.01%	9590
2022 Q1	–	Sell	-15,600	Closed	-$425K	–	14076
2021 Q4	$425K	Sell	15,600 -1,500	-9%	-$42.9K	﹤0.01%	10069
2021 Q3	$471K	Buy	+17,100	New	+$449K	﹤0.01%	10016
2021 Q2	–	Sell	-7,000	Closed	-$238K	–	14020
2021 Q1	$238K	Sell	7,000 -1,100	-14%	-$42K	﹤0.01%	11348
2020 Q4	$270K	Buy	+8,100	New	+$296K	﹤0.01%	9249
2020 Q3	–	Sell	-16,800	Closed	-$463K	–	10377
2020 Q2	$463K	Sell	16,800 -1,900	-10%	-$45K	﹤0.01%	7213
2020 Q1	$300K	Sell	18,700 -16,800	-47%	-$398K	﹤0.01%	7340
2019 Q4	$848K	Sell	35,500 -3,600	-9%	-$73.2K	﹤0.01%	5904
2019 Q3	$690K	Buy	39,100 +25,200	+181%	+$487K	﹤0.01%	6208
2019 Q2	$356K	Sell	13,900 -4,400	-24%	-$123K	﹤0.01%	7315
2019 Q1	$532K	Sell	18,300 -18,700	-51%	-$485K	﹤0.01%	6687
2018 Q4	$485K	Buy	37,000 +11,900	+47%	+$190K	﹤0.01%	6436
2018 Q3	$508K	Sell	25,100 -7,600	-23%	-$172K	﹤0.01%	6663
2018 Q2	$773K	Buy	32,700 +11,700	+56%	+$301K	﹤0.01%	5650
2018 Q1	$473K	Buy	21,000 +3,000	+17%	+$79K	﹤0.01%	5964
2017 Q4	$561K	Sell	18,000 -28,100	-61%	-$830K	﹤0.01%	5477
2017 Q3	$1.44M	Buy	46,100 +21,000	+84%	+$400K	﹤0.01%	3817
2017 Q2	$431K	Buy	+25,100	New	+$429K	﹤0.01%	5328
2016 Q1	–	Sell	-2,000	Closed	-$36K	–	7331
2015 Q4	$36K	Sell	2,000 -7,500	-79%	-$132K	﹤0.01%	7550
2015 Q3	$176K	Buy	9,500 +7,000	+280%	+$175K	﹤0.01%	6312
2015 Q2	$61K	Buy	2,500 +1,300	+108%	+$29.5K	﹤0.01%	7521
2015 Q1	$25K	Sell	1,200 -2,100	-64%	-$37K	﹤0.01%	7767
2014 Q4	$51K	Sell	3,300 -5,600	-63%	-$79.5K	﹤0.01%	7177
2014 Q3	$116K	Sell	8,900 -7,300	-45%	-$110K	﹤0.01%	6272
2014 Q2	$324K	Sell	16,200 -25,200	-61%	-$373K	﹤0.01%	4960
2014 Q1	$788K	Buy	41,400 +34,200	+475%	+$650K	﹤0.01%	3735
2013 Q4	$122K	Buy	7,200 +700	+11%	+$10.7K	﹤0.01%	5449
2013 Q3	$101K	Buy	6,500 +5,700	+713%	+$72.4K	﹤0.01%	5339
2013 Q2	$10K	Buy	+800	New	+$8.18K	﹤0.01%	6235

Other funds holding INSM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's INSM Position: Q1 2026 in Review

Citadel Advisors increased its Insmed (INSM) stake by 89% in Q1 2026, buying an estimated $158M and bringing the position to 2,182,571 shares worth $357M. The position accounts for 0.06% of the portfolio, ranked #260.

Citadel Advisors first reported a position in INSM in Q2 2013 and has held it in 46 quarters since. 670 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

Citadel Advisors held 2,182,571 shares of Insmed worth $357M as of Q1 2026.
Citadel Advisors bought 1,025,276 Insmed shares in Q1 2026, an estimated $158M.
Insmed made up 0.06% of Citadel Advisors's portfolio in Q1 2026, its #260 holding.
Citadel Advisors first reported a position in Insmed in Q2 2013 and has held it in 46 quarters since.
670 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.